4.97

3.88% -0.19

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $4.97, with a volume of 416.61K. It is down -3.88% in the last 24 hours and down -28.94% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Previous Close:

$5.16

Open:

$5.11

24h Volume:

416.61K

Relative Volume:

0.42

Market Cap:

$546.44M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-4.1074

EPS:

-1.21

Net Cash Flow:

$-120.82M

1W Performance:

-17.33%

1M Performance:

-28.94%

6M Performance:

-34.82%

1Y Performance:

-40.95%

1-Day Range:

$4.945

$5.20

1-Week Range:

$4.945

$6.00

52-Week Range:

$4.945

$13.01

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

140

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

Tango Therapeutics Inc Stock (TNGX) Latest News

Nov 04, 2024

Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year LowHere's What Happened - MarketBeat

Nov 04, 2024

Oct 31, 2024

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio - Simply Wall St

Oct 31, 2024

Oct 30, 2024

Tango Therapeutics (NASDAQ:TNGX) Stock Rating Reaffirmed by HC Wainwright - Defense World

Oct 30, 2024

Oct 29, 2024

Tango Therapeutics (NASDAQ:TNGX) Reaches New 12-Month Low Following Insider Selling - MarketBeat

Oct 29, 2024

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Oct 29, 2024

Tango Therapeutics target held at $13 by H.C. Wainwright - Investing.com

Oct 29, 2024

Oct 28, 2024

Tango Therapeutics (NASDAQ:TNGX) Sees Strong Trading VolumeHere's Why - MarketBeat

Oct 28, 2024

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 17.7% - MarketBeat

Oct 28, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $4,348,710.00 in Stock - MarketBeat

Oct 28, 2024

Tango Therapeutics (NASDAQ:TNGX) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 28, 2024

Tango Therapeutics sees $4.3 million stock sale by Boxer Capital - Investing.com Canada

Oct 28, 2024

Oct 25, 2024

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 8.7%Time to Buy? - MarketBeat

Oct 25, 2024

Oct 24, 2024

Tango Therapeutics sees $6.1 million stock sale by Boxer Capital - Investing.com Australia

Oct 24, 2024

Oct 23, 2024

Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 625,000 Shares - MarketBeat

Oct 23, 2024